Skip to main content

Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway.

Publication ,  Journal Article
Kopetz, S; Overman, M; Chang, DZ; Glover, KY; Shureiqi, I; Wolff, RA; Abbruzzese, JL; Eng, C
Published in: J Clin Oncol
April 20, 2008

PURPOSE: The current strategy of drug development has been criticized as being highly inefficient. In 2004, the US Food and Drug Administration (FDA) released recommendations to improve this process, including a push for increased use of enrichment trials. It is unclear to what extent aspects of this "Critical Path Initiative" have been adopted in trial designs in metastatic colorectal cancer. METHODS: A systematic review was conducted of actively enrolling treatment trials in metastatic colorectal cancer. Trials were identified from the National Cancer Institute's clinicaltrials.gov and Investigative Drug Branch databases. Trials were categorized based on the number of prior treatments allowed, phase of the trial, agent mechanism of action, and FDA approval status of agents under investigation. RESULTS: One hundred two trials are enrolling, with a combined enrollment goal of more than 20,000 patients. Thirteen percent of trials investigated an agent not yet FDA-approved for any oncology indication. The most common study design was a phase II study limited to previously untreated patients; compared with the remaining trials, these phase II trials were more than 10 times more likely to only use agents FDA-approved for colorectal cancer. Three percent of patients were enrolled onto trials enriched for tumor characteristics that were hypothesized to improve clinical benefit. CONCLUSION: Current clinical trials for metastatic colorectal cancer are deficient in the investigation of agents directed at a novel therapeutic target, overuse phase II studies of FDA-approved agents, and fail to incorporate enrichment trial designs as encouraged by the FDA initiative.

Duke Scholars

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

April 20, 2008

Volume

26

Issue

12

Start / End Page

2000 / 2005

Location

United States

Related Subject Headings

  • United States Food and Drug Administration
  • United States
  • Oncology & Carcinogenesis
  • Neoplasm Metastasis
  • Humans
  • Drug Approval
  • Colorectal Neoplasms
  • Clinical Trials, Phase II as Topic
  • Clinical Trials as Topic
  • Antineoplastic Agents
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kopetz, S., Overman, M., Chang, D. Z., Glover, K. Y., Shureiqi, I., Wolff, R. A., … Eng, C. (2008). Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway. J Clin Oncol, 26(12), 2000–2005. https://doi.org/10.1200/JCO.2007.13.2407
Kopetz, Scott, Michael Overman, David Z. Chang, Katrina Y. Glover, Imad Shureiqi, Robert A. Wolff, James L. Abbruzzese, and Cathy Eng. “Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway.J Clin Oncol 26, no. 12 (April 20, 2008): 2000–2005. https://doi.org/10.1200/JCO.2007.13.2407.
Kopetz S, Overman M, Chang DZ, Glover KY, Shureiqi I, Wolff RA, et al. Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway. J Clin Oncol. 2008 Apr 20;26(12):2000–5.
Kopetz, Scott, et al. “Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway.J Clin Oncol, vol. 26, no. 12, Apr. 2008, pp. 2000–05. Pubmed, doi:10.1200/JCO.2007.13.2407.
Kopetz S, Overman M, Chang DZ, Glover KY, Shureiqi I, Wolff RA, Abbruzzese JL, Eng C. Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway. J Clin Oncol. 2008 Apr 20;26(12):2000–2005.

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

April 20, 2008

Volume

26

Issue

12

Start / End Page

2000 / 2005

Location

United States

Related Subject Headings

  • United States Food and Drug Administration
  • United States
  • Oncology & Carcinogenesis
  • Neoplasm Metastasis
  • Humans
  • Drug Approval
  • Colorectal Neoplasms
  • Clinical Trials, Phase II as Topic
  • Clinical Trials as Topic
  • Antineoplastic Agents